164 related articles for article (PubMed ID: 18035195)
1. Pharmacokinetic and pharmacodynamic properties of a single intravenous dose of ibutilide fumarate: a phase I, randomized, open-label, increasing-dose study in healthy Chinese men.
Li Y; Tian L; Huang Y; Hua L
Clin Ther; 2007 Sep; 29(9):1957-66. PubMed ID: 18035195
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and safety profile of ivabradine in healthy Chinese men: a phase I, randomized, open-label, increasing single- and multiple-dose study.
Jiang J; Tian L; Huang Y; Li Y; Xu L
Clin Ther; 2013 Dec; 35(12):1933-45. PubMed ID: 24332196
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study.
Ellenbogen KA; Stambler BS; Wood MA; Sager PT; Wesley RC; Meissner MC; Zoble RG; Wakefield LK; Perry KT; Vanderlugt JT
J Am Coll Cardiol; 1996 Jul; 28(1):130-6. PubMed ID: 8752805
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic properties of rosuvastatin after single-dose, oral administration in Chinese volunteers: a randomized, open-label, three-way crossover study.
Li Y; Jiang X; Lan K; Zhang R; Li X; Jiang Q
Clin Ther; 2007 Oct; 29(10):2194-203. PubMed ID: 18042475
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic characteristics of aranidipine sustained-release, enteric-coated tablets in healthy Chinese men: a phase I, randomized, open-label, single- and multiple-dose study.
Jiang J; Tian L; Huang Y; Li Y; Xu L
Clin Ther; 2008 Jul; 30(7):1290-9. PubMed ID: 18691988
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of pilsicainide hydrochloride for injection in healthy Chinese volunteers: a randomized, parallel-group, open-label, single-dose study.
Qiu Q; Liu W; Li J; Wei Y; Yang K; Suo W; Wu W; Du H; Zhang Y; Zhao G; Zhou Z; Zheng Y; Lin Y
Clin Ther; 2014 Feb; 36(2):255-63. PubMed ID: 24480637
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of ibutilide in patients with heart failure due to left ventricular systolic dysfunction.
Tisdale JE; Overholser BR; Sowinski KM; Wroblewski HA; Amankwa K; Borzak S; Kingery JR; Coram R; Zipes DP; Flockhart DA; Kovacs RJ
Pharmacotherapy; 2008 Dec; 28(12):1461-70. PubMed ID: 19025427
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of 8-hour intravenous infusion of NXY-059: a phase I, randomized, double-blind (within dose panels), placebo-controlled study in healthy Chinese volunteers.
Cheng YF; Jiang J; Hu P; Reinholdsson I; Guo W; Asenblad N; Nilsson D
Clin Ther; 2008 Dec; 30(12):2342-53. PubMed ID: 19167593
[TBL] [Abstract][Full Text] [Related]
9. Acute hemodynamic effects of intravenous ibutilide in patients with or without reduced left ventricular function.
Stambler BS; Beckman KJ; Kadish AH; Camm JA; Ellenbogen KA; Perry KT; VanderLugt JT
Am J Cardiol; 1997 Aug; 80(4):458-63. PubMed ID: 9285658
[TBL] [Abstract][Full Text] [Related]
10. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. The Ibutilide/Sotalol Comparator Study Group.
Vos MA; Golitsyn SR; Stangl K; Ruda MY; Van Wijk LV; Harry JD; Perry KT; Touboul P; Steinbeck G; Wellens HJ
Heart; 1998 Jun; 79(6):568-75. PubMed ID: 10078083
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators.
Stambler BS; Wood MA; Ellenbogen KA; Perry KT; Wakefield LK; VanderLugt JT
Circulation; 1996 Oct; 94(7):1613-21. PubMed ID: 8840852
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of ibutilide for termination of atrial fibrillation and flutter.
Ellenbogen KA; Clemo HF; Stambler BS; Wood MA; VanderLugt JT
Am J Cardiol; 1996 Oct; 78(8A):42-5. PubMed ID: 8903275
[TBL] [Abstract][Full Text] [Related]
13. Ibutilide for pharmacological cardioversion of atrial fibrillation and flutter: impact of race on efficacy and safety.
Gowda RM; Punukollu G; Khan IA; Wilbur SL; Vasavada BC; Sacchi TJ
Am J Ther; 2003; 10(4):259-63. PubMed ID: 12845389
[TBL] [Abstract][Full Text] [Related]
14. Use of ibutilide for cardioversion of recent-onset atrial fibrillation and flutter in elderly.
Gowda RM; Khan IA; Punukollu G; Mendoza C; Wilbur SL; Vasavada BC; Sacchi TJ
Am J Ther; 2004; 11(2):95-7. PubMed ID: 14999360
[TBL] [Abstract][Full Text] [Related]
15. Ibutilide in persistent atrial fibrillation refractory to conventional cardioversion methods.
Naegeli B; Straumann E; Bertel O
Int J Cardiol; 2005 Mar; 99(2):283-7. PubMed ID: 15749188
[TBL] [Abstract][Full Text] [Related]
16. Clinical comparison of ibutilide and propafenone for converting atrial flutter.
Sun JL; Guo JH; Zhang N; Zhang HC; Zhang P
Cardiovasc Drugs Ther; 2005 Jan; 19(1):57-64. PubMed ID: 15883757
[TBL] [Abstract][Full Text] [Related]
17. Effects of intravenous magnesium sulfate on the QT interval in patients receiving ibutilide.
Caron MF; Kluger J; Tsikouris JP; Ritvo A; Kalus JS; White CM
Pharmacotherapy; 2003 Mar; 23(3):296-300. PubMed ID: 12627926
[TBL] [Abstract][Full Text] [Related]
18. Atrial electrophysiological effects of ibutilide infusion in humans.
Schwartz RA; Langberg JJ
Pacing Clin Electrophysiol; 2000 May; 23(5):832-6. PubMed ID: 10833702
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
Zhao RK; Cheng G; Tang J; Song J; Peng WX
Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
[TBL] [Abstract][Full Text] [Related]
20. An open-label, single-dose, parallel-group, dose-increasing study comparing the pharmacokinetics and tolerability of pilsicainide hydrochloride in healthy Korean and Japanese male subjects.
Kim BH; Kim JR; Lim KS; Kim JW; Kim KP; Hong JH; Jang IJ; Shin SG; Yu KS; Tanaka T
Clin Ther; 2009 Mar; 31(3):609-18. PubMed ID: 19393851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
